OTIC News and Press, Otonomy Inc. From 01/06/22

Multiple clinical trial readouts for OTO-313 in tinnitus and OTO-413 in hearing loss expected during 2022 Current capital funds operations into second half of 2023 SAN DIEGO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceut...

SAN DIEGO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its participation in the H.C. Wainwright BioConnect Virtual Conference. A pre-recorded co...

SAN DIEGO, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference. Managem...

Otonomy, Inc. (OTIC) Q3 2021 Results Conference Call November 10, 2021 04:30 PM ET Company Participants Contessa Semaan - Vice President, Investor Relations at Westwicke Dr. David Weber - President and Chief Executive Officer Paul Cayer - Chief Financial and Business Officer Conference Call P...

Otonomy (NASDAQ:OTIC): Q3 GAAP EPS of -$0.19 misses by $0.01. Press Release Cash, cash equivalents, and short-term investments totaled $87.1 million as of September 30, 2021, compared to $86.3 million as of December 31, 2020. For further details see: Otonomy EPS misses by $0.01

OTO-313 Phase 2 trial in tinnitus ongoing with results expected in mid-2022 Enrollment nearly complete in OTO-413 Phase 2a cohort in hearing loss with results moved forward to early in second quarter of 2022 Initiating clinical safety evaluation of higher dos...

OTCQX:ACRGF, ADMA, AEVA, DADAAMPE, AMWL, APP, APPH, ASND, ATO, OTCPK:ATUSF, AZUL, BANX, BARK, BIOL, BKEP, BMBL, BOXL, BRFS, BRKS, BROS, BSQR, BW, BYND, BZH, CBAY, CCCS, CCMP, CGRN, CLSD, CLVR, CRCT, CYCC, DARE, DGII, DIS, EDRY, EGLX, ELMS, ENS, EVOK, FICO, FIGS, FOSL, FSM, GAU, GDRX, GEVO, OT...

ACST, OTCQX:ADDYY, ADNT, AER, AFMD, OTCPK:ALIZF, ALT, ARCO, ASC, ATXS, AY, BTAI, BWEN, DTIL, OTCPK:EMRAF, ENR, EOSE, EVGO, FOUR, FVRR, OTCQX:GDNSF, GIB, GMAB, GSL, OTCQX:IFNNY, INVZ, IS, KIO, KRNT, LODE, MCRB, ME, ML, MNDY, MOGO, MSGS, NEON, NMM, NOVN, OTIC, PDSB, OTCPK:PEYUF, PFGC, PRGO, PTE...

Otonomy (NASDAQ:OTIC) is scheduled to announce Q3 earnings results on Tuesday, November 9th, after market close. The consensus EPS Estimate is -$0.18 (+18.2% Y/Y) and the consensus Revenue Estimate is $0.02M (-60.0% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 0...

SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the third quarter 2021 and provide a corporate update at ...